Navigation Links
Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
Date:12/6/2012

uing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, our ability to secure new partnerships and collaborations, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2011, our Form 10-Q for the quarter ended September 30, 2012, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

(Logo: http://photos.prnewswire.com/prnh/20120131/LA44118LOGO)

CONTACTS:
Investors: Bernie Hertel,
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
2. Inovio Pharmaceuticals to Present at Noble Financial Life Sciences Conference
3. Inovios Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science
4. Inovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference
5. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
6. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
7. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
8. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
10. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
11. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... , April 23, 2015 /CNW/ - A new and ... award from North America,s ... Comparison won Silver in the "Sustainability, service" category ... The Brandcheck "Competitor Comparison" is a service that ... American and Global peers. This benchmarking process shows ...
(Date:4/23/2015)... 23, 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the pharmaceutical, biotechnology and medical ... and the United States , ... the first quarter of 2015 after the New York ... will be Thursday morning, May 14, 2015 Shanghai time). ...
(Date:4/23/2015)... , April 23, 2015 ... Equipment   Report Details   We ... a value of $101.3 billion in 2015 and will grow ... growth in the healthcare sectors around the world and increasing ... key growth factors in the global healthcare packaging ...
(Date:4/23/2015)... YORK , April 23, 2015  Propanc ... stage healthcare company, focuses on the development of ... cancer. The company lead product includes PRP, a ... trypsinogen and chymotrypsinogen, as well as the enzyme ... is also developing a combination of anti-cancer agents ...
Breaking Biology Technology:WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Healthcare Packaging Market Forecast 2015-2025 2Healthcare Packaging Market Forecast 2015-2025 3Healthcare Packaging Market Forecast 2015-2025 4Healthcare Packaging Market Forecast 2015-2025 5Healthcare Packaging Market Forecast 2015-2025 6Healthcare Packaging Market Forecast 2015-2025 7Healthcare Packaging Market Forecast 2015-2025 8Healthcare Packaging Market Forecast 2015-2025 9Healthcare Packaging Market Forecast 2015-2025 10Early Stage BioTech offers Plenty of Risk; Propanc Health Group Analyst Brief Issued by BrokerBank Securities, Inc. 2
... Oct. ... , ... 30, 2009 -- The Boston biotechnology industry will get an early look at biotech,s future ... 2009 at Harvard Medical School. , , ,At the one-day event, recently funded companies will ...
... In its newly published Lockton Market Update ... that the markets are in a relative state of calm ... The online update includes snapshots of more than two dozen ... officers and other executives. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090415/CG99351LOGO ...
... PRINCETON, N.J., Sept. 30 DOR BioPharma, Inc. (OTC Bulletin ... has completed a corporate name change from DOR BioPharma, Inc. ... of the name change, the Company,s shares of common stock ... as of today. , "We are pleased to ...
Cached Biology Technology:Boston Biotech R&D Conference to Showcase Next-Generation Newsmakers and Massachusetts as Leader in Biotech Discovery 2Boston Biotech R&D Conference to Showcase Next-Generation Newsmakers and Massachusetts as Leader in Biotech Discovery 3Commercial Insurance Buyers Benefit From Ample Capacity 2Commercial Insurance Buyers Benefit From Ample Capacity 3DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 2DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 3DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 4
(Date:4/17/2015)... 17, 2015 Increasing ... technological advancement to drive biometric systems market in ...   According to a recently released ... &  Opportunities, 2020 ", biometric systems market in ... growth at CAGR of over 22% through 2020. ...
(Date:4/10/2015)... , April 10, 2015 ... addition of the "Security Competitive Profiles - NEC" ... http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to supply ... to the market, with a company focus on the ... anticipated. Winning opportunities in the ...
(Date:4/2/2015)... -- At its 2015 ACMG Annual Clinical Genetics Meeting ... American College of Medical Genetics and Genomics (ACMG) announced ... Members of the ACMG Board of Directors serve as ... its policies and programs. ACMG is the national organization ... eventful time in medical genetics and genomics.  We are ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... wastewater fuel cell, researchers have coaxed common bacteria to ... Logan and colleagues at Penn State University had already ... using starter material that could theoretically be sourced from ... microbes to generate hydrogen. By tweaking their design, ...
... 2007) A major study that will provide a new ... conducted by the La Jolla Institute for Allergy & ... The five-year study, funded by the National Institute of ... Institutes of Health, could lead to revolutionary new approaches ...
... Nov. 12, 2007 Visually unsettling and intellectually provocative, John ... Chervinsky, a photographer with a strong background in physics, ... Experiment in Perspective at the University of Houston at 7 ... Hoffman Hall. The event is free and open to ...
Cached Biology News:Microbes churn out hydrogen at record rate 2NIH selects LIAI for major study on allergy molecular causes and possible treatments 2NIH selects LIAI for major study on allergy molecular causes and possible treatments 3NIH selects LIAI for major study on allergy molecular causes and possible treatments 4Art meets science: Engineer discusses his photographs in free UH lecture 2